Loading stock data…
CYRX
$10.21-0.14 (-1.35%)
Pre-Market$10.71+0.50 (+4.90%)· Last close May 4
Cryoport, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Cryoport, Inc. in the Industrials sector is trading at $10.21. The stock is currently 11% below its 52-week high of $11.45, remaining 11.3% above its 200-day moving average. Technical signals show neutral RSI of 54 and bearish MACD signal, explaining why CYRX maintains its current momentum and trend strength. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 54) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.21
Potential Upside
5%
Whystock Fair Value$10.72
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide. The company's Life Sciences Services segment provides temperature-controlled logistics and biostora...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$526.72M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
14.99%
Volume
Today's trading volume
602,204
Recent News
Cryoport (CYRX) Q1 2026 Earnings Transcript
As a reminder, Cryoport, Inc. has uploaded their first quarter 2026 in review document to the main page of the Cryoport, Inc. website. This document provides a review of Cryoport, Inc.'s financial and operational performance and the general business outlook. Before I turn the call over to Jerry, please note that because of the strategic partnership that has been established with DHL Group, and the related sale of Cryo PDP to DHL in June 2025, Cryo PDP's financials, which were previously a part of Cryoport, Inc.'s Life Sciences Services reportable segment, are now presented as discontinued operations.
CryoPort Q1 Earnings Call Highlights
CryoPort (NASDAQ:CYRX) reported first-quarter fiscal 2026 results that management said reflected continued momentum across its integrated services and products platform, highlighted by double-digit revenue growth in both reporting segments and improved profitability metrics. On the call, CEO Jerrel
CryoPort, Inc. (CYRX) Reports Q1 Loss, Tops Revenue Estimates
CryoPort (CYRX) delivered earnings and revenue surprises of -15.00% and +6.41%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Cryoport (CYRX) Q2 2025 Earnings Transcript
All statements that address our operating performance, events or developments that we expect or anticipate occurring in the future are forward-looking statements. In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections.
Cryoport (CYRX) Q1 2025 Earnings Transcript
Jerrell Shelton: Thank you, Todd. With us this afternoon is our Chief Financial Officer, Robert Stefanovich; our Chief Scientific Officer, Dr. Mark Sawicki; and our Vice President of Corporate Development and Investor Relations, Thomas Heinzen.